Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wells Fargo Downgrades Allstate to Underweight

Wells Fargo analyst Elyse Greenspan downgrades Allstate (NYSE:ALL) from Equal-Weight to Underweight.

byBenzinga Newsdesk

December 9, 2021

1 minute read

Wells Fargo analyst Elyse Greenspan downgrades Allstate (NYSE:ALL) from Equal-Weight to Underweight.

Aditxt Earlier Announced Its Psoriasis Clinical Program Will Now Be Slated For 2022 Instead Of Dec. 2021

By Bill Haddad

Today, 11:27 AM

Psoriasis First-in-Human (Phase I/IIa) program is slated for 2022 Type 1 Diabetes and Skin Allografting are planned to enter clinical trials in 2022 Pre-clinical investigational work has started in Multiple

ADTX

Analyst Ratings

What 9 Analyst Ratings Have To Say About Qualcomm

By Benzinga Insights

Today, 11:27 AM

Analysts have provided the following ratings for Qualcomm (NASDAQ:QCOM) within the last quarter:

QCOM

Keefe, Bruyette & Woods Maintains Outperform on Cadence Bank, Lowers Price Target to $32

By Benzinga Newsdesk

Today, 11:27 AM

Keefe, Bruyette & Woods analyst Catherine Mealor maintains Cadence Bank (NYSE:CADE) with a Outperform and lowers the price target from $35 to $32.

CADE

Cantor Fitzgerald Maintains Overweight on WM Technology, Lowers Price Target to $6.25

By Benzinga Newsdesk

Today, 11:27 AM

Cantor Fitzgerald analyst Pablo Zuanic maintains WM Technology (NASDAQ:MAPS) with a Overweight and lowers the price target from $11 to $6.25.

MAPS

Wells Fargo Downgrades Allstate to Underweight

Related Posts

Aditxt Earlier Announced Its Psoriasis Clinical Program Will Now Be Slated For 2022 Instead Of Dec. 2021

What 9 Analyst Ratings Have To Say About Qualcomm

Keefe, Bruyette & Woods Maintains Outperform on Cadence Bank, Lowers Price Target to $32

Cantor Fitzgerald Maintains Overweight on WM Technology, Lowers Price Target to $6.25